Century Therapeutics, Inc. (NASDAQ: IPSC) had its price target lowered by analysts at Chardan Capital from $17.00 to $11.00. They now have a "buy" rating on the stock.
Century Therapeutics, Inc. (NASDAQ: IPSC) had its price target lowered by analysts at HC Wainwright from $9.00 to $5.00. They now have a "buy" rating on the stock.
Century Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]